Pfizer (PFE) is planning to raise at least $5B through a U.S. dollar corporate bond offering to fund, among other things, its recently completed acquisition of obesity drugmaker Metsera, Bloomberg ...

Pfizer has a higher-yielding dividend, but it may not be safe. AbbVie has the better path to growth in 2026. But when you ...

The latest trading day saw Pfizer (PFE) settling at $26.8, representing a -1.87% change from its previous close.

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...

Pfizer’s chief strategist, Andrew Baum, M.D., is leaving his post two years after pivoting from a career-long tenure as a ...

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2026 dividend on the ...

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

Pfizer’s GLP-1 weight management treatment Xianweiying, is reportedly available for pre-order in China in the wake of ...

The healthcare giant has been investing heavily in its future growth.

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle ...

Andrew Baum, a former Citi analyst, has left his role as Pfizer's executive vice president and chief strategy and innovation ...

Pfizer’s GLP-1 weight management treatment Xianweiying is available for pre-order in China, ​a Reuters check on a local ...